179 related articles for article (PubMed ID: 38363979)
1. Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer.
Silvestri VL; Tran AD; Chung M; Chung N; Gril B; Robinson C; Difilippantonio S; Wei D; Kruhlak MJ; Peer CJ; Figg WD; Khan I; Steeg PS
Neuro Oncol; 2024 Jun; 26(6):1067-1082. PubMed ID: 38363979
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment.
Baker JHE; Kyle AH; Reinsberg SA; Moosvi F; Patrick HM; Cran J; Saatchi K; Häfeli U; Minchinton AI
Clin Exp Metastasis; 2018 Oct; 35(7):691-705. PubMed ID: 30196384
[TBL] [Abstract][Full Text] [Related]
4. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
Askoxylakis V; Ferraro GB; Kodack DP; Badeaux M; Shankaraiah RC; Seano G; Kloepper J; Vardam T; Martin JD; Naxerova K; Bezwada D; Qi X; Selig MK; Brachtel E; Duda DG; Huang P; Fukumura D; Engelman JA; Jain RK
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26547932
[TBL] [Abstract][Full Text] [Related]
6. Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.
Nounou MI; Adkins CE; Rubinchik E; Terrell-Hall TB; Afroz M; Vitalis T; Gabathuler R; Tian MM; Lockman PR
Pharm Res; 2016 Dec; 33(12):2930-2942. PubMed ID: 27528392
[TBL] [Abstract][Full Text] [Related]
7. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
[TBL] [Abstract][Full Text] [Related]
8. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
Gril B; Palmieri D; Bronder JL; Herring JM; Vega-Valle E; Feigenbaum L; Liewehr DJ; Steinberg SM; Merino MJ; Rubin SD; Steeg PS
J Natl Cancer Inst; 2008 Aug; 100(15):1092-103. PubMed ID: 18664652
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Kodack DP; Chung E; Yamashita H; Incio J; Duyverman AM; Song Y; Farrar CT; Huang Y; Ager E; Kamoun W; Goel S; Snuderl M; Lussiez A; Hiddingh L; Mahmood S; Tannous BA; Eichler AF; Fukumura D; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3119-27. PubMed ID: 23071298
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice.
Rothwell WT; Bell P; Richman LK; Limberis MP; Tretiakova AP; Li M; Wilson JM
Cancer Res; 2018 Nov; 78(21):6171-6182. PubMed ID: 30154145
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
12. HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive marker.
Gril B; Wei D; Zimmer AS; Robinson C; Khan I; Difilippantonio S; Overstreet MG; Steeg PS
Neuro Oncol; 2020 Nov; 22(11):1625-1636. PubMed ID: 32386414
[TBL] [Abstract][Full Text] [Related]
13. Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.
Bloom MJ; Jarrett AM; Triplett TA; Syed AK; Davis T; Yankeelov TE; Sorace AG
BMC Cancer; 2020 Apr; 20(1):359. PubMed ID: 32345237
[TBL] [Abstract][Full Text] [Related]
14. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
Falchook GS; Moulder SL; Wheler JJ; Jiang Y; Bastida CC; Kurzrock R
Ann Oncol; 2013 Dec; 24(12):3004-11. PubMed ID: 24158411
[TBL] [Abstract][Full Text] [Related]
15. The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.
Dong R; Ji J; Liu H; He X
Crit Rev Oncol Hematol; 2019 Nov; 143():20-26. PubMed ID: 31449983
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.
Iwata H; Narabayashi M; Ito Y; Saji S; Fujiwara Y; Usami S; Katsura K; Sasaki Y
Int J Clin Oncol; 2013 Aug; 18(4):621-8. PubMed ID: 23011099
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors.
Yin O; Xiong Y; Endo S; Yoshihara K; Garimella T; AbuTarif M; Wada R; LaCreta F
Clin Pharmacol Ther; 2021 May; 109(5):1314-1325. PubMed ID: 33118153
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
Lockman PR; Mittapalli RK; Taskar KS; Rudraraju V; Gril B; Bohn KA; Adkins CE; Roberts A; Thorsheim HR; Gaasch JA; Huang S; Palmieri D; Steeg PS; Smith QR
Clin Cancer Res; 2010 Dec; 16(23):5664-78. PubMed ID: 20829328
[TBL] [Abstract][Full Text] [Related]
19. HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab--a case report.
Church DN; Bahl A; Jones A; Price CG
J Neurooncol; 2006 Sep; 79(3):289-92. PubMed ID: 16821088
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]